UCB Pharmaceuticals report highlights impact of rheumatoid arthritis

UCB Pharmaceuticals has published new research which illustrates the impact of rheumatoid arthritis (RA) on the health and quality of life of female sufferers.

The company presented results from its recent Good Days survey at a meeting of the European League Against Rheumatism in Rome, revealing that 72 per cent of women on pain medication as a result of RA experience discomfort on a daily basis.

According to the study, a majority of female RA sufferers also feel that the condition impacts their self-confidence and work productivity, with many having to leave their jobs as a result.

The survey was conducted across Europe and the US between July and August 2009 and involved almost 2,000 women.

Scott Fleming, global communications manager for immunology for UCB, said: “Insights from this study help us better understand the true impact of the disease and reinforce the urgent need for fast-acting treatments to help improve the lives of those living with RA.”

Earlier this week, UCB announced the agreement of a deal to increase its stake in cancer drug specialist Wilex, allowing it to expand its presence in the oncology market.